Not Yet RecruitingNot Applicable

Early Detection of COPD Exacerbations Using Home Monitoring Device

United States30 participantsStarted 2026-05

Plain-language summary

The goal of this observational study is to evaluate the safety and effectiveness of a home-monitoring device (RespirAI) in the early detection of COPD exacerbations in adults (age \>21) with physician-diagnosed COPD who are at high risk for exacerbations. The study will collect data from participants with COPD that will be analyzed using an AI-based algorithm to predict exacerbation events. The device's predictions will then be compared against clinically documented exacerbations to assess detection accuracy.

Who can participate

Age range21 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age \>21 years. * Physician-diagnosed COPD at least 6 months prior to screening visit. * Two or more moderate COPD exacerbations in the past 6 months or 1 severe exacerbation during the past 6 months. * Free of exacerbation for 1 month before enrollment. Exclusion Criteria: * Unable or willing to sign an informed consent. * Unable to complete the 6-minute walk test due to physical or mental health conditions. * Patients with cardiac pacemaker, defibrillators, or other implanted electronic devices. * Pregnancy * Study clinician determines that the patient is unable or unwilling to comply with all study procedures.

What they're measuring

Sensitivity

Timeframe: 6 months

False alam rate

Timeframe: 6 months

Trial details

NCT IDNCT07554352

SponsorRespirAI US Inc

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-05

Contact for this trial

Tamar Sobol

(617) 615-6799‬ info@respriai.com

View on ClinicalTrials.gov More COPD Exacerbation trials